Description

Targene focused on tissue targeting adeno-associated virus (AAV) and customed targeting plasmid research and development with a starting of cartilage targeting AAV. Our short-term objectives are scientific study service and license out based on our current products. We also aimed at exploring the potential application of tissue targeting AAV in gene therapy by pre-clinical and clinical trials as our long period objectives. Targene aims to provide tissue targeting recombinant AAV by direct evolution technology to solve the lack of targeting of the wild type AAV. Our current customers are bone and joint laboratories in Hong Kong, China mainland and overseas. We also provide license out service to other friendly companies to broaden our market. And by collaborating with clinicians, our future potential customers will be certain patients that need gene therapy.